Morfinesulfaat Retard Teva (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Morfinesulfaat Retard Teva, is an opioid analgesic presented as an extended‑release oral tablet for oral use. It treats moderate to severe acute pain, chronic cancer pain, post‑operative pain, and chronic non‑cancer pain requiring opioid therapy in appropriate patients.

GNH USA supplies Morfinesulfaat Retard Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine Sulfate is an opioid analgesic used to manage pain through central nervous system pathways.

- Moderate to severe acute pain: provides rapid analgesia for short‑term severe pain episodes. - Chronic cancer pain: offers sustained pain control for patients with malignant disease. - Post‑operative pain: reduces pain following surgical procedures. - Chronic non‑cancer pain requiring opioid therapy: maintains long‑term analgesia when other treatments are insufficient.

Morphine Sulfate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: sensation of queasiness. - Vomiting: expulsion of stomach contents. - Drowsiness: increased sleepiness. - Dizziness: light‑headed sensation. - Dry mouth: reduced salivation. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Anaphylaxis: life‑threatening allergic reaction. - Adrenal insufficiency: impaired cortisol production. - Dependence or addiction: potential for misuse. - Seizures: rare convulsive episodes.

Before prescribing Morfinesulfaat Retard Teva, clinicians should evaluate patient‑specific factors and monitor for safety concerns.

- Assess pain level and opioid tolerance: determine baseline analgesic needs. - Monitor for respiratory depression: especially in opioid‑naïve individuals or when combined with CNS depressants. - Evaluate renal and hepatic function: adjust therapy if organ impairment is present. - Avoid use in patients with significant respiratory compromise: contraindicated in severe asthma or COPD exacerbations. - Use caution in the elderly: increased sensitivity to sedative effects. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Morphine Sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): potential for serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased morphine plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced analgesic effect. - Diuretics: may exacerbate hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding.